• Explore /
  • Poster
  • / Final results of CORE-001: A phase-2, single arm study of cretostimogene grenadenorepvec in combination with pembrolizumab in patients with BCG-unresponsive, non-muscle invasive bladder cancer with carcinoma in situ.

Final results of CORE-001: A phase-2, single arm study of cretostimogene grenadenorepvec in combination with pembrolizumab in patients with BCG-unresponsive, non-muscle invasive bladder cancer with carcinoma in situ.

Abstract Video & Slides Poster

Authors

null

Roger Li

Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Roger Li , Paras H Shah , Tyler F. Stewart , Trinity Bivalacqua , Donald L. Lamm , Daniel M. Geynisman , Joshua J Meeks , Edward M. Uchio , Joseph M Jacob , Rian J. Dickstein , Shane Pearce , James M. Burke , Gary D. Steinberg

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Urothelial Cancer - Local-Regional Disease

Clinical Trial Registration Number

NCT04387461

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 4601)

DOI

10.1200/JCO.2024.42.16_suppl.4601

Abstract #

4601

Poster Bd #

296

Abstract Disclosures

Similar Posters

First Author: Ashish M. Kamat

First Author: Roger Li

First Author: Ashish M. Kamat

First Author: Arjun Vasant Balar